Cerebral microbleeds are predictive of mortality in the elderly.

Department of Radiology, C2-S, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.
Stroke (Impact Factor: 6.16). 03/2011; 42(3):638-44. DOI: 10.1161/STROKEAHA.110.595611
Source: PubMed

ABSTRACT To investigate the prognostic value of cerebral microbleeds (CMB) regarding overall, cardiovascular-related, and stroke-related mortality and to investigate possible differences based on a cerebral amyloid angiopathy-type and nonlobar distribution of microbleeds.
We included 435 subjects who were participants from the nested MRI substudy of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cox proportional hazard models were applied to estimate the risk of overall, cardiovascular-related, and stroke-related death associated with microbleeds in general and microbleeds with a lobar distribution suggestive of the presence of cerebral amyloid angiopathy. The corresponding Kaplan-Meier survival curves were calculated.
Subjects with >1 CMB had a 6-fold risk of stroke-related death compared to subjects without CMB (hazard ratio, 5.97; 95% CI, 1.60-22.26; P=0.01). The diagnosis of nonlobar microbleeds was associated with >2-fold risk of cardiovascular death compared to subjects without microbleeds (hazard ratio, 2.67; 95% CI, 1.23-5.81; P=0.01). Subjects with probable cerebral amyloid angiopathy-type microbleeds had >7-fold risk of stroke-related death compared to subjects without CMB (hazard ratio, 7.20; 95% CI, 1.44-36.10; P=0.02).
This is the first study investigating the association between microbleeds and risk of overall, cardiovascular-related, and stroke-related mortality in an elderly population. Our findings indicate that the diagnosis of microbleeds is potentially of clinical relevance. Larger studies are needed to expand our observations and to address potential clinical implications and cost-benefits of such a policy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: β-Amyloid plaques (Aβ plaques) in the brain are associated with cerebral amyloid angiopathy (CAA). Imaging agents that could target the Aβ plaques in the living human brain would be potentially valuable as biomarkers in patients with CAA. A new series of (18)F styrylpyridine derivatives with high molecular weights for selectively targeting Aβ plaques in the blood vessels of the brain but excluded from the brain parenchyma is reported. The styrylpyridine derivatives, 8a-c, display high binding affinities and specificity to Aβ plaques (K(i) = 2.87, 3.24, and 7.71 nM, respectively). In vitro autoradiography of [(18)F]8a shows labeling of β-amyloid plaques associated with blood vessel walls in human brain sections of subjects with CAA and also in the tissue of AD brain sections. The results suggest that [(18)F]8a may be a useful PET imaging agent for selectively detecting Aβ plaques associated with cerebral vessels in the living human brain.
    Journal of Medicinal Chemistry 12/2011; 54(23):8085-98. · 5.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral microbleeds (MBs) are small chronic brain hemorrhages which are likely caused by structural abnormalities of the small vessels of the brain. Owing to the paramagnetic properties of blood degradation products, MBs can be detected in vivo by using specific magnetic resonance imaging (MRI) sequences. Over the last decades, the implementation of these MRI sequences in both epidemiological and clinical studies has revealed MBs as a common finding in many different populations, including healthy individuals. Also, the topographic distribution of these MBs has been shown to be potentially associated with specific underlying vasculopathies. However, the clinical and prognostic significance of these small hemorrhages is still a matter of debate as well as a focus of extensive research. In this article, we aim to review the current knowledge on the pathophysiology and clinical implications of MBs, with special emphasis on the links between lobar MBs, cerebral amyloid angiopathy, and Alzheimer’s disease.
    Alzheimer's Research and Therapy 06/2014; 6(33). · 4.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral microbleeds (CMB) are small haemosiderin deposits, detected with varying sensitivity by specific MRI sequences. CMB prevalence increases most clearly and reliably with age, but CMB are also associated with various acquired and heritable cerebral vasculopathies (most commonly arteriolosclerosis and amyloid angiopathy). CMB often coincide with the other radiological features of small vessel disease, cortical microinfarction, lacunar infarction and periventricular white matter hyperintensity. CMB distribution may suggest an underlying cause; in particular, lobar-restricted or corticosubcortical CMB suggest amyloid angiopathy. In both ischaemic stroke and intracerebral haemorrhage, CMB appear to be a marker of underlying vasculopathy severity, and therefore a predictor of recurrence. Although CMB are also associated with several broad clinical neurological impairments (cognitive impairment, depression and gait instability), it is debatable whether CMB themselves are causative. The clinical implications of CMB detection remain unclear. Thrombolysis for ischaemic stroke is not contraindicated. It is uncertain whether more conservative antithrombotic strategies are warranted if CMB are detected in patients with symptomatic vascular disease or atrial fibrillation. Studies (observational and randomized) of various treatment strategies in patients with CMB and these concomitant conditions are required to resolve these treatment dilemmas.
    Journal of Clinical Neuroscience 05/2013; · 1.25 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014